Dilip J. Mehta, M.D., Ph.D. is the former Senior Vice President of US Clinical Research at Pfizer, Inc., where he was responsible for clinical research (Phase I, II and III), including the design and implementation of clinical protocols, statistical analysis and data processing, and submissions of New Drug Applications ("NDA"s) for Pfizer's pharmaceutical pipeline. During Dr. Mehta's tenure at Pfizer, he supervised NDA submissions for many of the company's current top-selling drugs, including Norvasc, Zololft, Zithromax, Diflucan and Viagra. Dr. Mehta managed a staff of over 450 scientists with an annual budget in excess of $350 million, and established clinical research teams in Canada, China, India and Latin America. Dr. Mehta currently serves on the Psychopharmacology Advisory Committee of the FDA, is a member of the board of directors of Spectrum Pharmaceuticals, Inc., Esvee Pharmaceuticals Pvt Ltd. (India), Bharat Serums & Vaccines Limited (India), and is a member of the Scientific Board of Myomatrix Molecular Technologies LLC. Dr. Mehta received his M.B.B.S., M.D. and Ph.D. from the University of Bombay.